Invivyd (IVVD) Total Non-Current Liabilities (2020 - 2024)
Invivyd (IVVD) posted Total Non-Current Liabilities of $62.0 million for Q4 2024, down 21.31% on a QoQ basis from $78.8 million in Q3 2024, and up 21.49% year-over-year from $51.0 million in Q1 2024.
Invivyd (IVVD) Total Non-Current Liabilities (2020 - 2024) Analysis & Trends
Invivyd's Total Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $62.0 million for Q4 2024.
- Quarterly Total Non-Current Liabilities rose 21.49% year-over-year to $62.0 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $62.0 million (up 21.49% YoY) and the FY2024 annual result came in at $62.0 million, up 21.49% from the prior year.
- Total Non-Current Liabilities was $62.0 million for Q4 2024 at Invivyd, down from $78.8 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $96.9 million in Q1 2022 and bottomed at $13.1 million in Q4 2020.
- A 5-year average of $50.8 million and a median of $49.2 million in 2022 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2021 — Total Non-Current Liabilities jumped 374.4% — and 2022, when it plunged 56.18%.
- Invivyd's Total Non-Current Liabilities stood at $13.1 million in 2020, then soared by 374.4% to $62.1 million in 2021, then tumbled by 56.18% to $27.2 million in 2022, then jumped by 87.57% to $51.0 million in 2023, then rose by 21.49% to $62.0 million in 2024.
- Business Quant data shows IVVD's Total Non-Current Liabilities at $62.0 million in Q4 2024, $78.8 million in Q3 2024, and $36.7 million in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 110.28 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 19.49 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 1.98 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 746.94 Mn |
| 10 | Invivyd | 104.07 Mn | -122.62 Mn | 16.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 61.98 Mn |
| Sep 30, 2024 | 78.76 Mn |
| Jun 30, 2024 | 36.70 Mn |
| Mar 31, 2024 | 36.97 Mn |
| Dec 31, 2023 | 51.01 Mn |
| Sep 30, 2023 | 27.72 Mn |
| Dec 31, 2022 | 27.20 Mn |
| Sep 30, 2022 | 47.30 Mn |
| Jun 30, 2022 | 69.77 Mn |
| Mar 31, 2022 | 96.88 Mn |
| Dec 31, 2021 | 62.07 Mn |
| Dec 31, 2020 | 13.08 Mn |